Evidence map›Paper›PMID 35392893›Full record

ArticleBMC women's health2022

Knowledge and compliance towards alendronate therapy among postmenopausal women with osteoporosis in Palestine.

Asma Radwan, Naser Shraim, Josephean Elaraj, Anwar Hamad, Dana Fatayer, Bayan Jarar, Ayoub Johar, Areen Zriqah

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC women's health, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.5field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Asma RadwanDepartment of Pharmacy, College of Medicine and Health Sciences, An-Najah National University, P.O. Box 7, Nablus, Palestine.
Naser ShraimDepartment of Pharmacy, College of Medicine and Health Sciences, An-Najah National University, P.O. Box 7, Nablus, Palestine. n_shraim@najah.edu.
Josephean ElarajDepartment of Pharmacy, College of Medicine and Health Sciences, An-Najah National University, P.O. Box 7, Nablus, Palestine.
Anwar HamadDepartment of Pharmacy, College of Medicine and Health Sciences, An-Najah National University, P.O. Box 7, Nablus, Palestine.
Dana FatayerDepartment of Pharmacy, College of Medicine and Health Sciences, An-Najah National University, P.O. Box 7, Nablus, Palestine.
Bayan JararDepartment of Pharmacy, College of Medicine and Health Sciences, An-Najah National University, P.O. Box 7, Nablus, Palestine.
Ayoub JoharDepartment of Pharmacy, College of Medicine and Health Sciences, An-Najah National University, P.O. Box 7, Nablus, Palestine.
Areen ZriqahDepartment of Pharmacy, College of Medicine and Health Sciences, An-Najah National University, P.O. Box 7, Nablus, Palestine.
An-Najah National University · PS

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPostmenopausal women compliance to alendronate therapy is suboptimal due to the complex dosing requirements. The poor compliance may increase their potential of fractures and the prevalence of side effects. In this study, the compliance of osteoporotic women on bisphosphonate therapy to the complex dosing instructions and their knowledge of alendronate-interactions were assessed.

methodsThis is a cross-sectional study, using self-administered questionnaire involving 224 osteoporotic women on alendronate therapy, who visited the orthopedic clinics and community pharmacies in the West Bank. Data was collected using a validated questionnaire consisting of 4 sections and analyzed by descriptive statistics. Moreover, associations between patient's socio-demographic characteristics and the extent of compliance and knowledge of alendronate interactions are established in this study.

resultsA total of 300 questionnaires were distributed and 224 were completed. The median compliance score to alendronate dosing instructions was 5 out of a possible maximum 7, and the median knowledge score about alendronate interactions was 7 out of a possible maximum 14. Factors found to affect either or both the knowledge and compliance to alendronate dosing instructions were, residency, and the source of instructions.

conclusionThis study identified the importance of compliance and knowledge gaps among postmenopausal women treated with alendronate. Therefore, appropriate knowledge about the importance of proper compliance to dosing instructions and avoidance of interactions is of a great benefit for maximizing clinical effectiveness, lowering fracture risk and prevention of adverse effects of alendronate among patients treated with alendronate in Palestine.

Indexed as

Bone Density Conservation AgentsOsteoporosisOsteoporosis, PostmenopausalAlendronateCross-Sectional StudiesFemaleHumansPostmenopauseAlendronateBone Density Conservation AgentsAlendronateComplianceDosing instructionsOsteoporosisPalestine

Identifiers

PMID35392893
PMCPMC8991824
OpenAlexW4223468256

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.